Economic times, July3, 2007 The Indian Patent Appellate Board (IPAB) on Monday heard a case that will decide whether S Chandrasekaran, former controller general of patents, will be allowed to hear Novartis appeal for Glivec, or if a new person will be appointed for the case. The Swiss drug major had earlier objected to the [...]
No Comments »
Filed under: News, Patent Litigation
Times of India, June 19, 2007 The much-awaited appeal proceedings in a cancer drug patent case could not begin on Monday as Swiss major Novartis AG, turning the tables on the government, raised a conflict-of-interest objection to the composition of the two-member bench of the Intellectual Property Appellate Board (IPAB). How can an officer who [...]
No Comments »
Filed under: News, Patent Litigation, TRIPS
Financial Express, June 20, 2007 The Intellectual Property Appellate Board (IPAB), which has been formed to give a verdict on various patent cases across the country, may reject Novartis objection on the presence of S Chandrasekharan, the former patent controller, on IPAB. Novartis had objected to Chandrasekharans presence on the board saying he was responsible [...]
No Comments »
Filed under: Article, News, Patent Litigation, TRIPS
THE HINDU, May 01, 2007 Norwegian Minister of International Development Erik Solheim has urged Novartis to withdraw its case against India, challenging a clause of the Indian Patent (Amendment) Act, which does not grant patents to medicines that are new forms of an existing drug or “ever-greened” rather than innovations. Last year, Doctors Without Borders [...]
No Comments »
Filed under: Article, News
In a rather predictable move, Novartis, the swiss multinational company which holds patent for a many medicines used for treating camcer, leukemia, malaria and many others including the the anti retro-viral AIDS medicine has challenged the contentious Section 3(d) introduced via the 2005 Amendments to India’s Patent Act. This unique section which has been specifically [...]
No Comments »
Filed under: News, Patent Litigation, TRIPS
In 1997, Novartis AG filed a patent application in the Chennai ( Madras) Patent Controller’s office for the beta-crystalline of Imatinib Mesylate, brand name Glivec (Gleevec) on the ground that they invented the beta crystalline salt form (imatinib mesylate) of the free base, imatinib. In 2003, it was granted Exclusive Marketing Rights (EMR) for marketing [...]
No Comments »
Filed under: Article, Campaign, News
Medical Patent News , March 8, 2007 A court in Chennai, India, last month heard arguments in the case regarding Novartis claims to Gleevec Patents in India. Some HIV/AIDS advocacy groups are calling on Novartis to drop its legal challenge, saying that if the company wins the case it could restrict access to antiretroviral drugs [...]
No Comments »
Filed under: Campaign, News
Novartisboycott tagged on Del.icio.us